Tango Therapeutics (TNGX) Non Operating Income (2020 - 2026)

Tango Therapeutics' Non Operating Income history runs 7 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 59.86% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $5.8 million (up 49.57% YoY), while the FY2025 annual figure was $9.7 million, up 27.43% from the prior year.
• Non Operating Income was $1.1 million for Q1 2026 at Tango Therapeutics, down from $3.1 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $3.8 million in Q3 2024 to a low of -$4.6 million in Q4 2024.
• Historically, Non Operating Income has averaged $1.0 million across 5 years, with a median of $1.1 million in 2026.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income jumped 2029.27% in 2022, then plunged 2376.47% in 2023.
• A 5-year view of Non Operating Income shows it stood at $102000.0 in 2022, then slumped by 2376.47% to -$2.3 million in 2023, then tumbled by 98.15% to -$4.6 million in 2024, then soared by 166.51% to $3.1 million in 2025, then plunged by 64.74% to $1.1 million in 2026.
• The last three Non Operating Income figures came in at $1.1 million (Q1 2026), $3.1 million (Q4 2025), and $705000.0 (Q3 2025), per Business Quant data.